Deshpande Laboratories Pvt. Ltd.

TCG Lifesciences Pvt. Limited (formerly "Chembiotek Research International"​) is a leading global Contract Researchand Manufacturing Services (CRAMS) company in the area of drug discovery and development. We started our operations in 2001 in Kolkata, India and currently have our presence in the United States, Europe, and Japan.
We have a strong talent pool of 800+ qualified and trained scientists (including 150+ PhDs), drawn from the best domestic and international institutes and industry. Our services span chemistry, in vitro and in vivo pharmacology, analytical development and validation, and specialty chemicals. We offer specific/functional solutions to integrated projects across multiple therapeutic areas with specific focus on Inflammation & Pain, Infectious Diseases, Central Nervous System and Oncology. Our research infrastructure includes world-class chemistry and biology laboratories, animal facility, electrophysiology laboratory, BSL 2 laboratory, and cGMP facilities at our R&D centers.
Our Offerings:
DISCOVERY SERVICES
Functional Chemistry
• Scaffolds & Building Blocks
• Library Synthesis
• Parallel Synthesis
• Medicinal Chemistry Singletons
• Solid Phase and Solution Phase Peptide Synthesis
Functional Biology
• In vitro Pharmacology
• ADME
• Pharmacokinetics and Pharmacodynamics (PK/PD)
• In vitro Toxicology
• In vivo Pharmacology
Fully Integrated Services
• Medicinal Chemistry Design
• Lead Generation
• Lead Optimization
• Preclinical Candidate Selection

DEVELOPMENT SERVICES
• Rapid Scale-Up and cGMP Kilo Labs
• Route Evaluation
• Hazard Assessment & Reaction Calorimetry
• Process R&D
• Clinical Trial Materials Preparation
Analytical Services
• cGMP Analytical Lab
• Methods Development & Validation
• Forced Degradation Studies
• Impurity Profile Determination
• Impurity Isolation and Characterization
• Preparative Chromatography (chiral, SFC, and HPLC)
• Reference Standards Management
• ICH Stability Studies
MANUFACTURING SERVICES:

Strand Life Sciences is a Bangalore-based bioinformatics company founded in 2000 by entrepreneurs from the Indian Institute of Science. Strand’s mission is to support precision medicine across the entire R&D lifecycle, from the lab to the clinic to data analysis. To that end, Strand has developed tools, platforms and services that span these disciplines. Key achievements include a cutting edge NGS liquid biopsy assay for early detection of oral cancer from saliva; a knowledge-base for interpretation of solid tumor and heme variants with over 500 genes, 20,000 variants, 110 FDA drugs and 80,000 clinical trials; a CAP and NABL-accredited genomics lab that has tested ≈10,000 samples in oncology, germline cancer, and rare diseases; Strand NGS, a software platform for secondary and tertiary analysis of NGS data; StrandOmics, a HIPAA-compliant, cloud-based platform for germline and somatic variant interpretation and reporting, used to generate clinical reports on all the ≈10,000 samples tested in our labs; and StrandIris, a fully automated, HIPAA-compliant cloud solution for interpretation and reporting of somatic variants. Underpinning these achievements is a strong track record of delivery on software development, assay development and biomarker studies projects with leading US-based instrument, diagnostics, pharmaceutical and biotech companies, a customer-base spanning ≈200 academics and diagnostics companies, and ≈25,000 citations of products developed at Strand since 2005.

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world. It has been growing at about 25.5% CAGR over the last 5 years and crossed the $1.9 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 69% of its revenue coming from global business.

Currently ranked 9th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology and Oncology in India. It is also known for its range of products in other hospital-based therapeutic segments in the EU and US.

Intas operates 15 formulation, R&D and distribution facilities, of which 10 are in India, and the rest in the UK and Mexico. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars and NDDS products.

Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “biosimilars for billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies.

The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP certified manufacturing facility complemented with a GLP compliant QC lab.

Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces of our excellence.

KYinno is dedicated to oncology drug discovery service and customized product development, with a focus on immuno-oncology and next-generation kinase inhibitor discovery.

Our service platforms include:
- Engineered custom cell line development
- Cell-based assay validation and compound screening
- Phage display library and hybridoma technology for antibody drug discovery
- Cancer cell panel compound profiling and biomarker discovery

Our products include:
- Engineered reporter cell lines
- Antibody and proteins with fully validated functions in reporter cell lines

Our team members have years of experience in the pharmaceutical and biotechnology industry in both China and U.S.